Posted by Michael Wonder on 22 Dec 2016
GPhA to President-Elect Trump: generic drug and biosimilar competition key to lowering drug prices, expanding access to affordable medicines
20 December 2016 - The Generic Pharmaceutical Association shares President Elect Donald J. Trump and the incoming Administration’s commitment to lowering drug costs.
In a memo to the President-elect, the Generic Pharmaceutical Association (GPhA) outlines a series of solutions that the incoming president and lawmakers can embrace today to expand access and increase patient and health system savings.
“Generic and biosimilar medicines are a readymade solution to high drug costs,” said Chip Davis, President and CEO of GPhA. “Unleashing the full potential of these medicines will require a bipartisan effort that includes patients, pharmacists, doctors, payors, supply chain partners and others who rely on access to safe, effective and more affordable medicines. It is important that policymakers pursue patient-centric and market-based solutions that enhance competition and expedite generic market entry to bring down prices and improves patient access to medicines.”
